Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

This publication has 66 references indexed in Scilit:

• Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
  New England Journal of Medicine, 2013
• Emerging Roles of ADAMTSs in Angiogenesis and Cancer
  Cancers, 2012
• Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
  Proceedings of the National Academy of Sciences, 2012
• An immune-active tumor microenvironment favors clinical response to ipilimumab
  Cancer Immunology, Immunotherapy, 2011
• Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
  Clinical Cancer Research, 2011
• High Lymphoid Enhancer-Binding Factor-1 Expression Is Associated with Disease Progression and Poor Prognosis in Chronic Lymphocytic Leukemia
  Hematology Reports, 2010
• Emerging Roles of the EBF Family of Transcription Factors in Tumor Suppression
  Molecular Cancer Research, 2009
• CRTAM Confers Late-Stage Activation of CD8+ T Cells to Regulate Retention within Lymph Node
  The Journal of Immunology, 2009
• The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
  Nature Immunology, 2008
• BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
  Nature Immunology, 2003